{"id":2774,"date":"2021-07-13T05:30:00","date_gmt":"2021-07-13T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-presents-interim-report-january-june-2021\/"},"modified":"2021-07-13T05:30:00","modified_gmt":"2021-07-13T05:30:00","slug":"xvivo-presents-interim-report-january-june-2021","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/","title":{"rendered":"XVIVO presents interim report January-June 2021"},"content":{"rendered":"
\n

Second quarter 2021 (Apr 1 – Jun 30)<\/strong>
\u2022 Net sales amounted to SEK 59.3 million (30.4), corresponding to an increase of 95 percent in SEK and 116 percent in local currencies. Net sales of non-durable goods amounted to SEK 56.3 million (28.0), corresponding to an increase of 101 percent in SEK and 124 percent in local currencies.
\u2022 Machine perfusion accounted for 52 percent (39) of net sales.
\u2022 Net sales in Business area Thoracic amounted to SEK 49.9 million (30.3) and Abdominal SEK 9.4 million (-).
\u2022 Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 8.4 million (-1.0), corresponding to an adjusted EBITDA margin of 14 percent (-3). Reported EBITDA amounted to SEK -1.5 million (-5.5), corresponding to an EBITDA margin of -3 percent (-18).
\u2022 Adjusted operating profit (EBIT) amounted to SEK 0.6 million (-8.2). Reported EBIT amounted to SEK -9.3 million (-12.7).
\u2022 Net profit amounted to SEK -8.9 million (-16.0). Earnings per share amounted to SEK -0.31 (-0.60).
\u2022 Cash and cash equivalents at the end of the quarter amounted to SEK 311.4 million (140.0).
\u00a0
Significant events during the quarter<\/strong>
\u2022 A 510(k) application for Kidney Assist Transport was filed with the FDA in the US.
\u2022 In the UK, NICE issued guidelines recommending EVLP\u00a0as the standard arrangement for preservation of lungs.
\u2022 The number of shares and votes in XVIVO Perfusion AB (publ) increased by 33,261 following exercise of warrants under incentive program 2019\/2021.<\/p>\n

The period 2021 (Jan 1 – Jun 30)<\/strong>
\u2022 Net sales amounted to SEK 117.6 million (76.9), corresponding to an increase of 53 percent in SEK and 68 percent in local currencies. Net sales of non-durable goods amounted to SEK 111.1 million (72.2), corresponding to an increase of 54 percent in SEK and 70 percent in local currencies.
\u2022 Machine perfusion accounted for 52 percent (34) of net sales.
\u2022 Net sales in Business area Thoracic amounted to SEK 96.3 million (76.8) and Abdominal SEEK 21.3\u00a0million (-).
\u2022 Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 14.7 million (4.1), corresponding to an adjusted EBITDA margin of 12 percent (5). Reported EBITDA amounted to SEK 9.7 million (2.1), corresponding to an EBITDA margin of 8 percent (3).
\u2022 Adjusted operating profit (EBIT) amounted to SEK -1.2 million (-10.7). Reported EBIT amounted to SEK -6.2 million (-12.7).
\u2022 Net profit amounted to SEK -2.9 million (-9.5). Earnings per share amounted to SEK -0.10 (-0.36).
\u2022 Cash and cash equivalents at the end of the period amounted to SEK 311.4 million (140.0).
\u00a0
Significant events during the period<\/strong>
\u2022 An article published in The New England Journal of Medicine, shows that oxygenated perfusion of donated liver before transplantation has a significant positive impact on the outcomes after transplantation.
\u2022 First patients transplanted in the Australian heart preservation study.
\u00a0
CEO comment<\/strong>
\u201cThe impact of the pandemic on hospitals varies between countries, which means that the rate at which transplant centers are returning to normal activity levels varies. The US, XVIVO\u2019s largest market, was quick to introduce an effective vaccination program, and the number of transplants for all major organs increased sharply in 2021 compared to 2020 and is now just above 2019 numbers. Other markets, such as certain European countries, started to recover later on, which has led to more patients waiting for new organs and the demand for transplants has never been higher. XVIVO\u2019s vision that \u201cNobody should die waiting for a new organ\u201d has become even more relevant during the pandemic.\u201c<\/p>\n<\/div>\n

\n

For further information, please contact:<\/strong><\/p>\n\n

Dag Andersson, CEO, +46 76 643 30 31, e-mail:\u00a0dag.andersson@xvivogroup.com
Kristoffer\u00a0Nordstr\u00f6m, CFO, +46 73 519 21 64, e-mail:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n

\n

Conference Call<\/strong><\/p>\n\n

CEO Dag Andersson och CFO Kristoffer Nordstr\u00f6m will present the report in a conference call today at 2 PM CET. Telephone UK: +44\u00a0333\u00a0300 0804, USA: +1\u00a0631\u00a0913 1422\u00a0or\u00a0Sweden:\u00a0+46\u00a08\u00a0566\u00a0426\u00a051 PIN: 52713996#<\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n\n

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.<\/a><\/p>\n<\/div>\n

\n

This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-07-13 07:30 CEST.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n\n

XVIVO Interim Report January June 2021<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Second quarter 2021 (Apr 1 – Jun 30)\u2022 Net sales amounted to SEK 59.3 million (30.4), corresponding to an increase…<\/p>\n","protected":false},"template":"","class_list":["post-2774","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q2","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en"],"acf":[],"yoast_head":"\nXVIVO presents interim report January-June 2021 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO presents interim report January-June 2021 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Second quarter 2021 (Apr 1 – Jun 30)\u2022 Net sales amounted to SEK 59.3 million (30.4), corresponding to an increase...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-june-2021\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-june-2021\\\/\",\"name\":\"XVIVO presents interim report January-June 2021 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2021-07-13T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-june-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-june-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-june-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO presents interim report January-June 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO presents interim report January-June 2021 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO presents interim report January-June 2021 - XVIVO","og_description":"Second quarter 2021 (Apr 1 – Jun 30)\u2022 Net sales amounted to SEK 59.3 million (30.4), corresponding to an increase...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/","name":"XVIVO presents interim report January-June 2021 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2021-07-13T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-june-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO presents interim report January-June 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}